| 2026-08-11 | 8-K | Form 8-K, Item 5.07 |
| 2026-07-30 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-29 | Proxy | Definitive proxy statement |
| 2026-06-22 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-29 | 8-K | Form 8-K, Item 7.01 |
| 2026-05-21 | 8-K | Form 8-K, Item 5.03 |
| 2026-05-12 | Deck | AnaptysBio Corporate Presentation May 2026 |
| 2026-05-12 | Press release | Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-12 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-11 | Press release | Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors |
| 2026-05-11 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-04 | Press release | Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference |
| 2026-04-28 | 10-K | Annual report on Form 10-K/A, FY25 |
| 2026-04-24 | Press release | Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim |
| 2026-04-24 | 8-K | Form 8-K/A, Item 9.01 |
| 2026-04-20 | Press release | Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collabo |
| 2026-04-20 | 8-K | Form 8-K, Item 1.01 |
| 2026-03-27 | Press release | First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement |
| 2026-03-27 | Press release | Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics |
| 2026-03-27 | Press release | Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update |
| 2026-03-27 | 8-K | Form 8-K, Item 1.01 |
| 2026-03-03 | Press release | Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-03 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-03 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-05 | Press release | Anaptys Announces Participation at Upcoming Investor Conferences |
| 2026-01-09 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-08 | Press release | Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro |
| 2026-01-06 | Press release | Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-11-26 | 8-K | Form 8-K, Item 7.01 |
| 2025-11-21 | 8-K | Form 8-K, Item 8.01 |
| 2025-11-21 | 8-K | Form 8-K, Item 8.01 |
| 2025-11-10 | 8-K | Form 8-K, Item 7.01 |
| 2025-11-04 | Press release | Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update |
| 2025-11-04 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-04 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-14 | Deck | Investor presentation · Oct 2025 |
| 2025-10-14 | 8-K | Form 8-K, Item 7.01 |
| 2025-09-29 | Deck | Investor presentation · Sep 2025 |
| 2025-09-29 | 8-K | Form 8-K, Item 7.01 |